Sabatolimab (Synonyms: MBG453) |
Katalog-Nr.GC64424 |
Sabatolimab (MBG453) ist ein hochaffiner, humanisierter IgG4 (S228P)-AntikÖrper, der auf TIM-3 abzielt, einen inhibitorischen Rezeptor, der adaptive und angeborene Immunantworten reguliert.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2252262-24-9
Sample solution is provided at 25 µL, 10mM.
Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells[1].
[1]. Andrew M. Brunner, et al. Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study. Blood (2020) 136 (Supplement 1): 1-2.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *